Shadows after the Light: Persistent Cytopenia Post–CAR T-cell Therapy:

Key Points

• Persistent cytopenia occurs in a significant number of patients following CAR T-cell therapy, impacting recovery timelines.
• At 6 months, 45% of patients exhibit ongoing cytopenia, highlighting the delayed immune recovery that challenges overall health.
• Analysis of patient records reveals a correlation between initial response and subsequent bone marrow function post therapy.
• Findings emphasize the importance of long-term hematologic monitoring, as late effects may influence clinical outcomes.